EP0641212A4 - Method and reagent for inhibiting cancer development. - Google Patents
Method and reagent for inhibiting cancer development.Info
- Publication number
- EP0641212A4 EP0641212A4 EP93911311A EP93911311A EP0641212A4 EP 0641212 A4 EP0641212 A4 EP 0641212A4 EP 93911311 A EP93911311 A EP 93911311A EP 93911311 A EP93911311 A EP 93911311A EP 0641212 A4 EP0641212 A4 EP 0641212A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- reagent
- cancer development
- inhibiting cancer
- inhibiting
- development
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/122—Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/123—Hepatitis delta
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/124—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes based on group I or II introns
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/126—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes involving RNAse P
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Public Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US882885 | 1978-03-02 | ||
US8910 | 1979-02-02 | ||
US88282292A | 1992-05-14 | 1992-05-14 | |
US88288592A | 1992-05-14 | 1992-05-14 | |
US93642292A | 1992-08-26 | 1992-08-26 | |
US93653192A | 1992-08-26 | 1992-08-26 | |
US07/936,532 US6492512B1 (en) | 1992-08-26 | 1992-08-26 | Method and reagent for treatment of lung cancer and other malignancies caused by the deregulation of L-MYC gene expression |
US936421 | 1992-08-26 | ||
US936110 | 1992-08-26 | ||
US936422 | 1992-08-26 | ||
US936531 | 1992-08-26 | ||
US07/936,110 US5610052A (en) | 1992-08-26 | 1992-08-26 | Enzymatic RNA with activity to ras |
US936532 | 1992-08-26 | ||
US07/936,421 US5750390A (en) | 1992-08-26 | 1992-08-26 | Method and reagent for treatment of diseases caused by expression of the bcl-2 gene |
US98713192A | 1992-12-07 | 1992-12-07 | |
US987131 | 1992-12-07 | ||
US612293A | 1993-01-19 | 1993-01-19 | |
US891093A | 1993-01-19 | 1993-01-19 | |
US6122 | 1993-01-19 | ||
PCT/US1993/004573 WO1993023057A1 (en) | 1992-05-14 | 1993-05-13 | Method and reagent for inhibiting cancer development |
US882822 | 1997-06-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0641212A1 EP0641212A1 (en) | 1995-03-08 |
EP0641212A4 true EP0641212A4 (en) | 1997-05-21 |
Family
ID=27580619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP93911311A Withdrawn EP0641212A4 (en) | 1992-05-14 | 1993-05-13 | Method and reagent for inhibiting cancer development. |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0641212A4 (en) |
JP (1) | JPH08502950A (en) |
AU (1) | AU687001B2 (en) |
CA (1) | CA2135499A1 (en) |
WO (1) | WO1993023057A1 (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2135646A1 (en) * | 1992-05-11 | 1993-11-25 | Kenneth G. Draper | Method and reagent for inhibiting viral replication |
US5646042A (en) * | 1992-08-26 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | C-myb targeted ribozymes |
AU2099095A (en) * | 1994-03-07 | 1995-09-25 | Immusol, Inc | Ribozyme therapy for restenosis |
US5834440A (en) * | 1994-03-07 | 1998-11-10 | Immusol Incorporated | Ribozyme therapy for the inhibition of restenosis |
US6103890A (en) * | 1994-05-18 | 2000-08-15 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids that cleave C-fos |
US6146886A (en) * | 1994-08-19 | 2000-11-14 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
EP0772678A4 (en) * | 1994-09-12 | 1999-10-20 | Hope City | Modulation of drug radiation resistant genes |
WO1996018733A2 (en) * | 1994-12-14 | 1996-06-20 | Innovir Laboratories, Inc. | Ribozyme-mediated inactivation of leukemia-associated rna |
US7034009B2 (en) | 1995-10-26 | 2006-04-25 | Sirna Therapeutics, Inc. | Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
EP1408111B1 (en) | 1995-10-26 | 2010-06-09 | Sirna Therapeutics, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
US6346398B1 (en) | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
WO1997018305A2 (en) * | 1995-11-14 | 1997-05-22 | Regents Of The University Of Minnesota | Method to prepare drug-resistant, non-malignant hematopoietic cells |
AU721758B2 (en) * | 1996-04-02 | 2000-07-13 | Gene Shears Pty. Limited | Asymmetric hammerhead ribozymes |
US6238917B1 (en) * | 1996-04-02 | 2001-05-29 | Commonwealth Scientific Industrial Research Organizaion | Asymmetric hammerhead ribozymes |
DK0808898T3 (en) * | 1996-05-24 | 2004-09-27 | Aventis Pharma Gmbh | Reagent and method for inhibiting N-ras expression |
US7329741B2 (en) * | 1996-06-05 | 2008-02-12 | Chiron Corporation | Polynucleotides that hybridize to DP-75 and their use |
US5807743A (en) * | 1996-12-03 | 1998-09-15 | Ribozyme Pharmaceuticals, Inc. | Interleukin-2 receptor gamma-chain ribozymes |
US6057156A (en) | 1997-01-31 | 2000-05-02 | Robozyme Pharmaceuticals, Inc. | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors |
US6482932B1 (en) | 1997-11-05 | 2002-11-19 | Ribozyme Pharmaceuticals, Incorporated | Nucleoside triphosphates and their incorporation into oligonucleotides |
US6617438B1 (en) | 1997-11-05 | 2003-09-09 | Sirna Therapeutics, Inc. | Oligoribonucleotides with enzymatic activity |
US6127535A (en) | 1997-11-05 | 2000-10-03 | Ribozyme Pharmaceuticals, Inc. | Nucleoside triphosphates and their incorporation into oligonucleotides |
US6995259B1 (en) | 1998-10-23 | 2006-02-07 | Sirna Therapeutics, Inc. | Method for the chemical synthesis of oligonucleotides |
US6875747B1 (en) * | 1999-05-24 | 2005-04-05 | Avi Bio Pharma, Inc. | Antisense to c-myc for treatment of polycystic kidney disease |
US6607915B1 (en) * | 1999-09-30 | 2003-08-19 | Isis Pharmaceuticals, Inc. | Antisense inhibition of E2A-Pbx1 expression |
US6682902B2 (en) | 1999-12-16 | 2004-01-27 | Schering Aktiengesellschaft | DNA encoding a novel RG1 polypeptide |
US7754435B2 (en) | 2000-09-21 | 2010-07-13 | Philadelphia Health And Education Corporation | Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms |
EP1354890B1 (en) * | 2000-12-28 | 2007-08-08 | Shionogi & Co., Ltd. | Chordin-like polypeptides and dna thereof |
EP1386004A4 (en) | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
US7205399B1 (en) | 2001-07-06 | 2007-04-17 | Sirna Therapeutics, Inc. | Methods and reagents for oligonucleotide synthesis |
EP1375661A1 (en) * | 2002-06-17 | 2004-01-02 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | The role of the N-myc - nm23H1/nm23H2 - cdc42 pathway in proliferation, differentiation and treatment of cancer |
US20040101915A1 (en) * | 2002-06-18 | 2004-05-27 | Irm Llc, A Delaware Limited Liability Company | Diagnosis and treatment of chemoresistant tumors |
EP1637144A4 (en) * | 2003-05-30 | 2010-01-13 | Nippon Shinyaku Co Ltd | Oligonucleic acid-bearing composite and pharmaceutical composition containing the composite |
EP2756845B1 (en) * | 2009-04-03 | 2017-03-15 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA |
CA2757613C (en) * | 2009-04-03 | 2023-10-17 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of kras by asymmetric double-stranded rna |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0387775A1 (en) * | 1989-03-16 | 1990-09-19 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Genetic construct for inhibiting RNA function |
WO1991004324A1 (en) * | 1989-09-25 | 1991-04-04 | Innovir Laboratories, Inc. | Ribozyme compositions and methods for use |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991018913A1 (en) * | 1990-06-07 | 1991-12-12 | City Of Hope | Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna |
WO1991018625A1 (en) * | 1990-06-07 | 1991-12-12 | City Of Hope | Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna |
EP0639226A1 (en) * | 1990-06-26 | 1995-02-22 | The Wistar Institute | Rna molecule for use in treating leukemias |
-
1993
- 1993-05-13 JP JP6500939A patent/JPH08502950A/en active Pending
- 1993-05-13 CA CA002135499A patent/CA2135499A1/en not_active Abandoned
- 1993-05-13 EP EP93911311A patent/EP0641212A4/en not_active Withdrawn
- 1993-05-13 WO PCT/US1993/004573 patent/WO1993023057A1/en not_active Application Discontinuation
- 1993-05-13 AU AU42489/93A patent/AU687001B2/en not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0387775A1 (en) * | 1989-03-16 | 1990-09-19 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Genetic construct for inhibiting RNA function |
WO1991004324A1 (en) * | 1989-09-25 | 1991-04-04 | Innovir Laboratories, Inc. | Ribozyme compositions and methods for use |
Non-Patent Citations (7)
Title |
---|
83RD ANN. MEET. AM. ASSOC. CANCER RES., MAY 20-23, 1992 , SAN DIEGO, CA * |
CHANG, E. & MILLER, P.: "Ras, an inner membrane transducer of growth stimuli", WICKSTROM, E. 'PROSPECTS FOR ANTISENSE NUCLEIC ACID THERAPY OF CANCER AND AIDS'; WILEY-LISS; 1991, pages 115 - 124, XP002027819 * |
HOLM, P. ET AL.: "CONSTRUCTION OF A RIBOZYME WITH CATALYTIC ACTIVITY AGAINST THE MRNA OF THE MULTIDRUG RESISTANCE-ASSOCIATED P-GLYCOPROTEIN .", PROC ANNU MEET AM ASSOC CANCER RES, (1992). VOL. 33, PP. 401. ABSTRACT 2393., XP000647577 * |
KASHANI-SABET M ET AL: "REVERSAL OF THE MALIGNANT PHENOTYPE BY AN ANTI-RAS RIBOZYME", ANTISENSE RESEARCH AND DEVELOPMENT, vol. 2, no. 1, 1992, pages 3 - 15, XP000576012 * |
KOBAYASHI H ET AL: "Cleavage of human MDR1 mRNA by a hammerhead ribozyme.", FEBS LETTERS, (1993 MAR 15) 319 (1-2) 71-4., XP002027820 * |
See also references of WO9323057A1 * |
STEPHENSON P ET AL: "IN VITRO CLEAVAGE OF AN N-RAS MESSENGER-LIKE RNA BY A RIBOZYME", ANTISENSE RESEARCH AND DEVELOPMENT, vol. 1, 1991, pages 261 - 268, XP000196553 * |
Also Published As
Publication number | Publication date |
---|---|
JPH08502950A (en) | 1996-04-02 |
AU687001B2 (en) | 1998-02-19 |
WO1993023057A1 (en) | 1993-11-25 |
CA2135499A1 (en) | 1993-11-25 |
EP0641212A1 (en) | 1995-03-08 |
AU4248993A (en) | 1993-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0641212A4 (en) | Method and reagent for inhibiting cancer development. | |
EP0642589A4 (en) | Method and reagent for inhibiting viral replication. | |
EP0586125A3 (en) | Method and kit for detecting explosives. | |
GB9612528D0 (en) | Method for diagnosing cancer | |
ZA961316B (en) | Benzopyran-containing compounds and method for their use. | |
GB2298613B (en) | Dual card and method therefor | |
EP0655625A3 (en) | Sensing elements and method for making same. | |
EP0587162A3 (en) | Information processing apparatus. | |
EP0592808A3 (en) | Commercial data masking. | |
IL114188A0 (en) | Method for idal-in access security | |
GR3019617T3 (en) | DNA detection method | |
EP0601848A3 (en) | System and method for knowledge based design. | |
EP0585944A3 (en) | Information processing method and apparatus. | |
EP0645630A3 (en) | Method of determining the presence of a pivka and a reagent therefor. | |
EP0584828A3 (en) | LSI automated design system. | |
EP0605108A3 (en) | Development processes. | |
IL103600A0 (en) | Method and kit for cancer diagnosis | |
EP0584776A3 (en) | Information processing method and apparatus. | |
GB2298502B (en) | Data processing method | |
GB2284054B (en) | Method for range determination | |
ZA93782B (en) | Determination method. | |
GB2266167B (en) | Communicating system and method for communicating data | |
ZA932652B (en) | Method for the elimination of non-specific reactions in immunoassays. | |
HUP9904330A3 (en) | Perfluoroalkylation method and reagent therefor | |
EP0578138A3 (en) | Gene-detecting method. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19941117 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
RHK1 | Main classification (correction) |
Ipc: C12N 15/52 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19970407 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20000517 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20041201 |